info:eu-repo/semantics/article
Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses
Fecha
2006-05-15Registro en:
Toscano, Marta Alicia; Commodaro, Alessandra G.; Ilarregui, Juan Martin; Bianco, German Ariel; Liberman, Ana Clara; et al.; Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses; American Association of Immunologists; Journal of Immunology; 176; 10; 15-5-2006; 6323-6332
0022-1767
1550-6606
CONICET Digital
CONICET
Autor
Toscano, Marta Alicia
Commodaro, Alessandra G.
Ilarregui, Juan Martin
Bianco, German Ariel
Liberman, Ana Clara
Serra, Horacio M.
Jun Hirabayashi
Rizzo, Luiz V.
Rabinovich, Gabriel Adrián
Resumen
Intraocular inflammatory diseases are a common cause of severe visual impairment and blindness. In this study, we investigated the immunoregulatory role of galectin-1 (Gal-1), an endogenous lectin found at sites of T cell activation and immune privilege, in experimental autoimmune uveitis (EAU), a Th1-mediated model of retinal disease. Treatment with rGal-1 either early or late during the course of interphotoreceptor retinoid-binding protein-induced EAU was sufficient to suppress ocular pathology, inhibit leukocyte infiltration, and counteract pathogenic Th1 cells. Administration of rGal-1 at the early or late phases of EAU ameliorated disease by skewing the uveitogenic response toward nonpathogenic Th2 or T regulatory-mediated anti-inflammatory responses. Consistently, adoptive transfer of CD4(+) regulatory T cells obtained from rGal-1-treated mice prevented the development of active EAU in syngeneic recipients. In addition, increased levels of apoptosis were detected in lymph nodes from mice treated with rGal-1 during the efferent phase of the disease. Our results underscore the ability of Gal-1 to counteract Th1-mediated responses through different, but potentially overlapping anti-inflammatory mechanisms and suggest a possible therapeutic use of this protein for the treatment of human uveitic diseases of autoimmune etiology.